Thalidomide induced remission of refractory diffuse large B-Cell Lymphoma post-allogeneic SCT.
Patients who relapse after High dose therapy and autologous stem cell transplant (ASCT) for Diffuse large B cell Lymphoma (DLBCL) have a poor prognosis with a median survival of only 3-6 month.1-2 This case demonstrates the ability of thalidomide at low doses to induce durable response in a patient with DLBCL who relapsed after full intensity allogeneic transplantation.
Tueger
S
S
Dept. of Haematology, Guy's & St Thomas' NHS Foundation Trust, London, UK.
Chen
F E
FE
Ahsan
G
G
McDonald
V
V
Andrews
V E
VE
Madrigal
J A
JA
Kazmi
M A
MA
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D016393:Lymphoma, B-Cell / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000628:therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D011859:Radiography; D012074:Remission Induction; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000627:therapeutic use*; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents; D013792:Thalidomide